Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle by Quarter
IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — U.S. product sales ($M) ($M)
Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle: $233M in Q2 2026, up 117.8% from a year earlier. That is the highest of the 9 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 233 | +117.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 188 | +138.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 183 | +173.1% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 144 | +300.0% | Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 107 | +791.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 79 | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 67 | – | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 36 | – | Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 12 | – | Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗ |
Cite this data
StockData. (2026). Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle ($M), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-imdelltra-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.